Kidney Week

Abstract: FR-PO925

Height Loss Is Associated With Decreased Kidney Function: The Japan Specific Health Checkups (J-SHC) Study

Session Information

• CKD: Epidemiology, Risk Factors, Prevention - II
  November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 2201 CKD (Non-Dialysis): Epidemiology‚ Risk Factors‚ and Prevention

Authors

• Kosugi, Takaaki, Department of Nephrology, Nara Medical University, Kashihara, Nara, Japan

Takaaki Kosugi,

• Eriguchi, Masahiro, Department of Nephrology, Nara Medical University, Kashihara, Nara, Japan

Masahiro Eriguchi,

• Yoshida, Hisako, Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Osaka, Japan

Hisako Yoshida,

• Tasaki, Hikari, Department of Nephrology, Nara Medical University, Kashihara, Nara, Japan

Hikari Tasaki,

• Nishimoto, Masatoshi, Department of Nephrology, Nara Medical University, Kashihara, Nara, Japan

Masatoshi Nishimoto,

• Matsui, Masaru, Department of Nephrology, Nara Medical University, Kashihara, Nara, Japan

Masaru Matsui,

• Samejima, Ken-ichi, Department of Nephrology, Nara Medical University, Kashihara, Nara, Japan

Ken-ichi Samejima,

• Iseki, Kunitoshi, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Kunitoshi Iseki,

• Fujimoto, Shouichi, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Shouichi Fujimoto,

• Konta, Tsuneo, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Tsuneo Konta,

• Moriyama, Toshiki, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Toshiki Moriyama,

• Yamagata, Kunihiro, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Kunihiro Yamagata,

• Narita, Ichiei, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Ichiei Narita,

• Kasahara, Masato, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Masato Kasahara,

• Shibagaki, Yugo, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Yugo Shibagaki,

• Kondo, Masahide, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Masahide Kondo,

• Asahi, Koichi, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Koichi Asahi,

• Watanabe, Tsuyoshi, Steering Committee of The Japan Specific Health Checkups (J-SHC) Study, Fukushima, Japan

Tsuyoshi Watanabe,

• Tsuruya, Kazuhiko, Department of Nephrology, Nara Medical University, Kashihara, Japan

Kazuhiko Tsuruya,

Background

Height loss that occurs with aging is a common phenomenon associated with musculoskeletal abnormalities, such as osteoporosis and sarcopenia. Notably, such height loss is also associated with cardiovascular disease and mortality. However, the relationship between height loss and kidney outcome remains unclear.

Methods

This is a longitudinal study based on data from the J-SHC Study from 2008 to 2014. The first three visits (visits 1–3) were used to estimate height loss, and kidney outcomes were evaluated using data from visit 3 to the last visit. Of 933,488 participants, we excluded participants based on the following criteria: 1) ≤4 visits during the study period, 2) less than three measurements of height during visits 1–3, 3) missing serum creatinine at baseline (visit 3), 4) a height below or above 3 standard deviations, 5) a baseline serum creatinine level of ≥8 mg/dL or <0.3 mg/dL. The annual height change (cm/year) for each participant was estimated using mixed-effects model, and participants were divided into five groups according to the quintile of the rate (Q1 to Q5). The association between height change and the incidence of 1.5-fold increase in serum creatinine level from baseline was analyzed using Cox regression analysis. The decline rates of eGFR (mL/min/1.73 m²/year) among the groups were compared using a linear mixed-effects model.

Results

The median rate of height change was −0.11 cm/year. During the median follow-up period of 26 months, 1,941 of 187,682 participants developed a 1.5-fold increase in serum creatinine levels. The adjusted hazard ratio (95% confidence interval) in participants with the steepest category of height loss (Q1) was 1.45 (1.26–1.67) compared with the reference (Q4). The decline rate of eGFR in Q1 (−1.25 mL/min/1.73 m²/year) was significantly higher than that of Q4 (−0.92 mL/min/1.73 m²/year) (p for interaction <0.001).

Conclusion

Height loss is associated with a rapid decline in kidney function.

Funding

• Government Support – Non-U.S.